What the policy lists
| Prior authorization | listed in the policy |
|---|
Cigna's documents for Skyrizi
- Skyrizi IV (risankizumab-rzaa) Prior Authorization Policy (policy IP0669)
- Skyrizi Subcutaneous Prior Authorization Policy (policy IP0670)
What your plan's policy says
The plan's document holds the details for this medicine.
What this medicine is used for
“SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.”
“active psoriatic arthritis in adults and pediatric patients 6 years of age and older.”
“moderately to severely active ulcerative colitis in adults.”
“Plaque Psoriasis SKYRIZI ® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.”
“Psoriatic Arthritis SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 6 years of age and older.”
“Ulcerative Colitis SKYRIZI is indicated for the treatment of moderately to severely active ulcerative colitis in adults.”
From the FDA label for Skyrizi, revised June 15, 2026. The label is shown in English as published. DailyMed. Your doctor decides what it is used for in your case.
Common questions
Does Cigna require prior authorization for Skyrizi?
Cigna's published policy lists prior authorization for Skyrizi.
How do I see the policy for my own plan and state?
Open the free KAIS guide, pick your plan, your type of plan, your state and your medicine, and it shows the policy your plan publishes, with the link to the plan's own document.
Not medical advice and not a decision on your claim. Your doctor and your plan decide.